What will the FDA's decision be on Atacicept by Vera Therapeutics in July 2026?
Markets
Every market on this event, moneyline first. Select one to compare it across platforms in the side panel.
| Outcome | Best | Azuro | Gemini | Kalshi | Limitless | Novig | Polymarket | Polymarket US |
|---|---|---|---|---|---|---|---|---|
Yes Winner | 96.0%Kalshi | — | — | — | — | — | — | |
No | 4.0%Kalshi | — | — | — | — | — | — |
Description from Kalshi. A cross-platform summary is generated once this event is matched across platforms.
If the FDA's decision on Atacicept by Vera Therapeutics in July 2026 is a full approval or an accelerated approval, the market resolves to Yes. This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. Atacicept is an investigational biological medicine developed by Vera Therapeutics that acts as a "double interceptor," blocking two proteins — called BAFF and APRIL — that instruct the immune system's B cells to overproduce a defective form of the antibody IgA. Think of BAFF and APRIL as two fuel lines feeding an immune fire in the kidney; atacicept is designed to shut off both simultaneously, dampening the abnormal immune response that drives kidney damage in IgA nephropathy (IgAN).
Discussion (0)
Log in to join the discussion.
No comments yet — start the discussion.